Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...

Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...